In the current work we hypothesized that using multiple markers described above will allow us to capture a wide range of CTCs using general breast cancer markers—MGB1, HER2 as well as epithelial (CK19, CDH1) and mesenchymal markers (VIM, CDH2, PLS3) for CTCs’ EMT phenotype determination. This evidence concerns the gene PLS3 and breast carcinoma.